BioSpace News Archive

Yellowbrick has partnered with ScaleMatrix to offer even more free access to powerful data solutions to researchers and companies actively working on a vaccine for the novel coronavirus, COVID-19.

PPE A95 Canadian respirator to help prevent the spread of COVID-19

Funding round to fuel new musculoskeletal and neural products, expand internationally, and deepen strategic alliances with the world’s leading cardiology centers

Konica Minolta Healthcare Americas, Inc. announced today that Rede™ PACS, the company’s newest medical image management solution for specialty clinics, and Rede Mini PACS for ultrasound and X-ray image management are now available for purchase in the United States. As medical imaging services expand at the point of care, particularly digital radiography and ultrasound, specialty care clinics and practices increasingly require solutions to view,

Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic

Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA

The easy-to-clean, glove-operable touchpad can help everyone from first responders to medical staff to average citizens help fight the spread of COVID-19

Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it is acquiring Tocagen’s retroviral replicating vector platform (RRV) in its entirety, including its investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC (now known as DB107), and several early-stag

The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split.

Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and other bleeding disorders, today announced the European Patent Office has issued the Company a FIX portfolio patent covering the lead clinical candidate, dalcinonacog alfa (DalcA) for Factor IX (FIX) replacement therapy, and the Company’s FIX preclinical gene therapy candidate, CB 2679d-GT. “This